GS Paper - 2 (Diseases)

Reliance Life Sciences (RLS), part of India's largest conglomerate, is expected to start phase I clinical studies of its indigenous Covid-19 vaccine soon. The Subject Expert Committee (SEC), which advises the drug regulator on vaccines and new drugs, reviewed the company’s application and is learnt to have recommended it for approval.


  1. The vaccine under development is a recombinant protein-based Covid-19 vaccine, and is expected to be launched by the first quarter 2022.
  2. The company started the development process last year, with the vaccine entering the pre-clinical stage in October.
  3. Reliance Life Sciences is a niche biotechnology player with differentiated products used to treat patients in critical care, and manufactures biosimilar products, plasma proteins and complex monoclonal antibodies. The company is augmenting its capacity to manufacture vaccines next year.
  4. RLS is operating a high capacity Covid-19 RT-PCR and antibody testing laboratory, and has developed a 'molecular transport medium’ for collection and transportation of Covid-19 swab samples.